We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
+9.22%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$10.2B
AUM Growth
-$9.59M
(-0.09%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-2.3%
Top 10 Holdings %
Top 10 Hldgs %
76.44%
Holding
39
New
5
Increased
9
Reduced
7
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$212M |
| 2 |
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
|
+$97.2M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$55.2M |
| 4 |
Celcuity
CELC
|
+$28.8M |
| 5 |
Avalo Therapeutics
AVTX
|
+$22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$393M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$256M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$79.9M |
| 4 |
PTC Therapeutics
PTCT
|
+$52M |
| 5 |
ORKA
Oruka Therapeutics
ORKA
|
+$40.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
GH Research
GHRS
$2.04B
| $25.3M | 0.25% |
1,800,000
| – | – |
|
|
27
Avalo Therapeutics
AVTX
$1.04B
| $21.1M | 0.21% |
+1,410,000
| New | +$22M |
|
28
Lexeo Therapeutics
LXEO
$398M
| $10.8M | 0.11% |
1,875,000
-1,425,000
| -43% | -$10.1M |
|
29
CALL
United Therapeutics
UTHR
$21.4B
| $10.3M | 0.1% |
+380,000
| New | +$189M |
|
|
WHWK
30
Whitehawk Therapeutics
WHWK
$251M
| $9.83M | 0.1% |
2,849,402
| – | – |
|
31
MannKind Corp
MNKD
$1.23B
| $5.39M | 0.05% |
2,200,000
-2,244,444
| -50% | -$10M |
|
|
32
CALL
Celcuity
CELC
$4.49B
| $3.05M | 0.03% |
+200,000
| New | +$21.8M |
|
33
Apogee Therapeutics
APGE
$10.2B
| – | – |
-500,000
| Closed | -$37.7M |
|
34
CALL
Ascendis Pharma A/S
ASND
$16.2B
| – | – |
-50,000
| Closed | -$625K |
|
35
Incyte
INCY
$24.4B
| – | – |
-135,000
| Closed | -$13.3M |
|
|
36
PTC Therapeutics
PTCT
$5.99B
| – | – |
-685,000
| Closed | -$52M |
|
|
RNAM
37
DELISTED
Avidity Biosciences
RNAM
| – | – |
-5,455,000
| Closed | -$393M |
|
|
38
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| – | – |
-2,100,000
| Closed | -$256M |
|
|
ORKA
39
Oruka Therapeutics
ORKA
$7.24B
| – | – |
-1,333,340
| Closed | -$40.4M |
|
Similar funds
BHCM
UE
PIF
EIG
LPC
HL
DCP
Avoro Capital Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Avoro Capital Advisors held 39 positions worth $10.2B, down 0.09% from $10.2B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Avoro Capital Advisors's Q1 2026 filing shows 5 new, 9 increased, 7 reduced and 7 closed positions. Its largest new stake was Cytokinetics: 3,333,333 shares worth $220M. The largest sale was Avidity Biosciences, an estimated $393M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.
- Avoro Capital Advisors's largest Q1 2026 buy was Cytokinetics: 3,333,333 shares worth $220M.
- Avoro Capital Advisors added most to Terns Pharmaceuticals in Q1 2026, an estimated $55.2M increase.
- Avoro Capital Advisors's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $79.9M.
- Avoro Capital Advisors fully exited Avidity Biosciences in Q1 2026, selling an estimated $393M.
- Avoro Capital Advisors's ten largest holdings make up 76% of its $10.2B portfolio in Q1 2026.
- Avoro Capital Advisors opened 5 new positions and closed 7 in Q1 2026.
- Avoro Capital Advisors's portfolio value fell 0.09% quarter-over-quarter to $10.2B.
Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.